OBJECTIVE: To estimate FT and its association with quality of life (QoL).
METHODS: This was an observational descriptive study conducted among cancer patients recommended for P&P care. Scores were estimated from September 2022 to February 2023 using official tools: the Functional Assessment for Chronic illness Treatment Compressive Score for Financial Toxicity (FACIT-COST) and the European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaires for Cancer (QLQ30).
RESULTS: From 150 patients (70 males and 80 females, mean age 54.96 ± 13.5 years), 92.6% suffered from FT. Eleven patients (7.3%) were under FT grade 0, 41 (27.3%) were FT grade 1, 98 (65.3%) were FT grade 2, and no patients were under FT grade 3. At criterial alpha 0.05 (95%CI), FT and the global score for HRQoL showed an association. Among inpatient department (IPD) expenses, medication bills contributed the greatest expense at 33%, and among outpatient department (OPD) expenses treatment expenses contributed 50% of the total. Breast cancer (30 cases, 20%) and oral cancer (26 cases, 17.3%) were the most frequent cancers.
CONCLUSIONS: FT measured using the COST tool showed an association with HRQoL.
UNASSIGNED: This paper refers to the insurance policies available for cancer patients irrespective of P&P care treatment.
目的:评估FT及其与生活质量(QoL)的关系。
方法:这是一项观察性描述性研究,在建议接受P&P治疗的癌症患者中进行。从2022年9月至2023年2月,使用官方工具对分数进行了估算:慢性疾病治疗的功能评估财务毒性评分(FACIT-COST)和欧洲癌症研究与治疗组织(EORTC)癌症生活质量问卷(QLQ30)。
结果:来自150名患者(70名男性和80名女性,平均年龄54.96±13.5岁),92.6%遭受FT。11例患者(7.3%)低于FT等级0,41例(27.3%)为FT等级1,98例(65.3%)为FT等级2,无患者低于FT等级3。在标准α0.05(95CI)下,FT和HRQoL的全球评分显示出相关性。在住院部(IPD)费用中,药费支出最大,为33%,在门诊部(OPD)费用中,治疗费用占总费用的50%。乳腺癌(30例,20%)和口腔癌(26例,17.3%)是最常见的癌症。
结论:使用COST工具测量的FT显示与HRQoL相关。
■本文涉及癌症患者的保险政策,而不考虑P&P护理治疗。